Table 1.
Clinical characteristics of the study subjects assigned to the add-on sitagliptin group and continued therapy with conventional antidiabetic agents at baseline
| Parameters | Sitagliptin (n = 45) | Conventional (n = 51) | p value |
|---|---|---|---|
| Age | 70 ± 8 | 69 ± 9 | 0.501 |
| Gender (m/f) | 29/16 | 33/18 | 0.574 |
| BMI | 25.5 ± 3.4 | 25.5 ± 4.4 | 0.956 |
| SBP (mmHg) | 131 ± 12 | 130 ± 16 | 0.643 |
| DBP (mmHg) | 74 ± 11 | 71 ± 12 | 0.256 |
| HR (beats/min) | 67 ± 12 | 69 ± 11 | 0.389 |
| Current smoker | 3 | 6 | 0.412 |
| TC (mmol/L) | 4.5 ± 0.8 | 4.5 ± 0.8 | 0.879 |
| HDL (mmol/L) | 1.3 ± 0.3 | 1.3 ± 0.4 | 0.996 |
| TG (mmol/L) | 1.5 ± 0.7 | 1.7 ± 1.0 | 0.176 |
| Crnn (μmol/L) | 76 ± 20 | 75 ± 21 | 0.805 |
| eGFR (mL/min per 1.73 m2) | 65 ± 16 | 67 ± 17 | 0.675 |
| FBG (mmol/L) | 6.8 ± 1.6 | 7.3 ± 1.9 | 0.560 |
| Hemoglobin A1c (%) | 6.9 ± 0.6 | 7.0 ± 0.6 | 0.560 |
| Hypertension | 38 | 40 | 0.313 |
| Dyslipidemia | 32 | 35 | 0.484 |
| Cerebrovascular disease | 5 | 7 | 0.471 |
| Cardiovascular disease | 23 | 33 | 0.127 |
| Medication for diabetes | |||
| Insulin | 0 | 0 | |
| Biguanides | 7 | 10 | 0.403 |
| Sulfonylureas | 10 | 11 | 0.566 |
| Others | 21 | 30 | 0.162 |
n number of study subjects, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, brPP brachial pulse pressure, HR heart rate, Current smoker number of current smokers, TC serum total cholesterol, HDL serum high-density lipoprotein cholesterol, TG serum triglyceride, Crnn serum creatinine, eGFR creatinine-based estimated glomerular filtration rate, FBG fasting blood glucose, Hypertension number of subjects with hypertension, Dyslipidemia number of subjects with dyslipidemia, Cerebrovascular disease number of subjects with cerebrovascular disease, Cardiovascular disease number of subjects with cardiovascular disease, Insulin number of subjects treated with insulin, Biguanides number of subjects treated with biguanides, Sulfonylureas number of subjects treated with sulfonylureas, Others number of subjects treated with antidiabetic agents other than insulin, biguanides or sulfonylureas